Search Results - "Buggé, Joshua"

Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo by DiTommaso, Tia, Cole, Julie M., Cassereau, Luke, Buggé, Joshua A., Hanson, Jacquelyn L. Sikora, Bridgen, Devin T., Stokes, Brittany D., Loughhead, Scott M., Beutel, Bruce A., Gilbert, Jonathan B., Nussbaum, Kathrin, Sorrentino, Antonio, Toggweiler, Janine, Schmidt, Tobias, Gyuelveszi, Gabor, Bernstein, Howard, Sharei, Armon

“…The translational potential of cell-based therapies is often limited by complications related to effectively engineering and manufacturing functional cells…”
Get full text

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody by Weaver, Jessica D., Stack, Edward C., Buggé, Joshua A., Hu, Changyun, McGrath, Lara, Mueller, Amy, Wong, Masie, Klebanov, Boris, Rahman, Tanzila, Kaufman, Rosemary, Fregeau, Christine, Spaulding, Vikki, Priess, Michelle, Legendre, Kristen, Jaffe, Sarah, Upadhyay, Dhruvkumar, Singh, Anirudh, Xu, Chang-Ai, Krukenberg, Kristin, Zhang, Yan, Ezzyat, Yassine, Saddier Axe, Dorothée, Kuhne, Michelle R., Meehl, Michael A., Shaffer, Donald R., Weist, Brian M., Wiederschain, Dmitri, Depis, Fabien, Gostissa, Monica

“…The presence of T regulatory (Treg) cells in the tumor microenvironment is associated with poor prognosis and resistance to therapies aimed at reactivating…”
Get full text

Vector Free Genome Editing of Human CD34+ Cells for Cell Therapy by Bridgen, Devin T, DiTommaso, Tia, Buggé, Joshua, Gilbert, Jonathan B, Bernstein, Howard, Sharei, Armon

“…While the ex vivo manipulation of primary cells has signaled a new era in the application of cell-based therapies, common methods to manipulate primary cells…”
Get full text

Abstract 4532: Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells by Dépis, Fabien, Hu, Changyun, Weaver, Jessica, McGrath, Lara, Klebanov, Boris, Buggé, Joshua, Umiker, Ben, Fregeau, Christine, Upadhyay, Dhruvkumar, Singh, Anirudh, Xu, Chang-Ai, Spaulding, Vikki, Priess, Michelle, Wong, Masie, Naheed, Seema, Zhang, Yan, Legendre, Kristin, Stack, Edward C., Mora, Alessandro, Willer, Margaret, Meetze, Kristan, Gostissa, Monica, Meehl, Michael A., Shaffer, Donald R.

“…Introduction: Immune checkpoint blockade (ICB) has revolutionized the treatment of many cancers, still most patients do not respond to PD-1 or CTLA-4…”
Get full text